Dewpoint Therapeutics Inc. has announced the selection of a development candidate for its TDP-43 program. The first-in-class small molecule is designed to correct disease-associated TDP-43 condensates ...

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, ...

Entrada Therapeutics Inc. has updated progress across its preclinical portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.

Incregen Therapeutics LLC has advanced INC-118, a glucose-dependent insulinotropic polypeptide (GIP) ligand antagonist ...

While Alzheimer’s disease is known for involving amyloid-b plaques and neurofibrillary tangles, it also involves metabolic dysfunction, further research into which could help scientists understand how ...

Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic ...

Generative AI has largely escaped the U.S. FDA’s regulatory purview up to now, but OpenAI seems poised to create a new source of regulatory angst for the agency. The company unveiled its ChatGPT ...

Ollin Biosciences Inc. is gearing up for global phase III trials this year after disclosing favorable top-line results from its randomized, head-to-head phase Ib Jade study comparing OLN-324, a ...

Annual biopharma financing values have fluctuated significantly over the past seven years, peaking during the pandemic-era surge in 2020 and 2021 before retreating in 2022. After rebounding to more ...

Investors poured a further $13 million into Vicentra BV for Kaleido, its insulin patch pump system, taking the total raised in the company’s series D financing round to $98 million. The funds come ...

Hisamitsu Pharmaceutical Co. Inc. President and CEO Kazuhide Nakatomi is leading a management buyout to take the company private, citing mounting drug pricing pressures and tougher listing ...

Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare ...